10:50 AM EDT, 09/12/2024 (MT Newswires) -- Johnson & Johnson ( JNJ )-owned (JNJ) Janssen-Cilag International said Thursday it filed a marketing authorization application with the European Medicines Agency for nipocalimab to treat generalized myasthenia gravis, a chronic autoimmune disease.

The submission is supported by phase 3 study data which showed nipocalimab's safety and tolerability were consistent with other studies.

Shares of Johnson & Johnson ( JNJ ) declined 1.1% in recent trading.

Price: 162.94, Change: -1.88, Percent Change: -1.14